| CUSTOMER |
CUSTOMER |
92%
|
During the three months ended March 31, 2026, revenues from delivering advertising campaigns via cold emails and social media sites were recognized from one customer who accounted for 100 % of this r… |
| Z-SQUARED-INC |
Z-SQUARED-INC |
90%
|
On April 27, 2026, Z Squared, Inc. (NASDAQ: ZSQR) (the Company”) issued a press release supplementing information related to its recently announced business combination with Coeptis Therapeutics Hold… |
| VY-GEN-BIO-INC |
VY-GEN-BIO-INC |
80%
|
In March 2025, the Company reached an agreement with Vy-Gen-Bio, Inc. ('Vy-Gen') to successfully license the exclusive worldwide development and commercialization rights to the GEAR™ (Gene Edited Ant… |
| ZSQR |
ZSQR |
72%
|
NC. formerly known as COEPTIS THERAPEUTICS HOLDINGS, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Three Months Ended March 31, 2026 March 31, 2025 OPERATING ACTIVITIES Net loss $ … |
| ZSQR |
ZSQR |
72%
|
Reciprocal relationship from ZSQR graph: Reciprocal relationship from COEP graph: Reciprocal relationship from ZSQR graph: Reciprocal relationship from COEP graph: NC. formerly known as COEPTIS THERA… |
| BULL-HORN-HOLDINGS-CORP |
BULL-HORN-HOLDINGS-CORP |
62%
|
risks, including: (i) the level and durability of customer demand for HPC capacity, which is presently driven substantially by demand for artificial intelligence and machine learning training and inf… |
| COEPTIS-PHARMACEUTICALS-LLC |
COEPTIS-PHARMACEUTICALS-LLC |
62%
|
tions through its direct and indirect subsidiaries SNAP Biosciences, Inc. and GEAR Therapeutics, Inc. (each majority owned), and Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., and Coeptis… |
| COEPTIS-THERAPEUTICS-HOLDINGS-INC |
COEPTIS-THERAPEUTICS-HOLDINGS-INC |
62%
|
risks, including: (i) the level and durability of customer demand for HPC capacity, which is presently driven substantially by demand for artificial intelligence and machine learning training and inf… |
| COEPTIS-THERAPEUTICS-INC-COEPTIS-PHARMACEUTICALS |
COEPTIS-THERAPEUTICS-INC-COEPTIS-PHARMACEUTICALS |
62%
|
tions through its direct and indirect subsidiaries SNAP Biosciences, Inc. and GEAR Therapeutics, Inc. (each majority owned), and Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., and Coeptis… |
| COMPANY-GEAR-THERAPEUTICS-INC |
COMPANY-GEAR-THERAPEUTICS-INC |
62%
|
cuit, or ASIC, mining hardware (including Antminer L7, L9, and DG1+ models) deployed across multiple mining algorithms (including SHA-256, Scrypt, and kHeavyHash). Key elements of the Company's minin… |
| CP-MERGER-SUB-INC |
CP-MERGER-SUB-INC |
62%
|
NOTE 15 – SEGMENT REPORTING Operating segments are components of an enterprise about which separate financial information is available and is evaluated regularly by management, namely the Chief Opera… |
| EMERGING-GROWTH-COMPANY |
EMERGING-GROWTH-COMPANY |
62%
|
and restrictions of preferred stock, including dividend rights, conversion rights, voting rights, terms of redemption, liquidation preference, sinking fund terms, and the number of shares constitutin… |
| GEAR-DEVERRA-THERAPEUTICS-INC |
GEAR-DEVERRA-THERAPEUTICS-INC |
62%
|
cuit, or ASIC, mining hardware (including Antminer L7, L9, and DG1+ models) deployed across multiple mining algorithms (including SHA-256, Scrypt, and kHeavyHash). Key elements of the Company's minin… |
| GEAR-THERAPEUTICS-INC |
GEAR-THERAPEUTICS-INC |
62%
|
risks, including: (i) the level and durability of customer demand for HPC capacity, which is presently driven substantially by demand for artificial intelligence and machine learning training and inf… |
| HOLDINGS-LLC-GROUP |
HOLDINGS-LLC-GROUP |
62%
|
risks, including: (i) the level and durability of customer demand for HPC capacity, which is presently driven substantially by demand for artificial intelligence and machine learning training and inf… |
| NEXGENAI-SOLUTIONS-GROUP-INC |
NEXGENAI-SOLUTIONS-GROUP-INC |
62%
|
y held companies, recorded as investments on the Company’s condensed consolidated balance sheets. The Company’s Chief Executive Officer and Chief Financial Officer each hold ownership interests in th… |
| REPORT-BIOTECHNOLOGY-SEGMENT-VY-GEN-BIO-INC |
REPORT-BIOTECHNOLOGY-SEGMENT-VY-GEN-BIO-INC |
62%
|
cuit, or ASIC, mining hardware (including Antminer L7, L9, and DG1+ models) deployed across multiple mining algorithms (including SHA-256, Scrypt, and kHeavyHash). Key elements of the Company's minin… |
| SKYCORE-DIGITAL-LLC |
SKYCORE-DIGITAL-LLC |
62%
|
nc. was not part of the Spin-Out and continues to be held by the Company following the Merger. Change in Business. Following the completion of the Merger and the Spin-Out, the Company's principal bus… |
| SNAP-BIOSCIENCES-INC |
SNAP-BIOSCIENCES-INC |
62%
|
tions through its direct and indirect subsidiaries SNAP Biosciences, Inc. and GEAR Therapeutics, Inc. (each majority owned), and Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., and Coeptis… |
